Financial PerformanceAvita delivered 3Q commercial revenue totaling $19.5M, reflecting growth of 44% year over year.
Market ExpansionThe FDA's approval of RECELL for broader applications expanded the Company's market reach, underscoring the product's versatility and efficacy.
Product DevelopmentFDA has granted 510(k) clearance for Cohealyx, a new collagen-based dermal matrix branded by AVITA Medical, which enhances AVITA’s comprehensive portfolio for addressing full-thickness wound care.